Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study
-
By
-
Mengwei Feng
-
Yunjie Wu
-
Chaoqing Xie
-
Jingxian Xing
-
Deguang Wang
-
Xue Liang
-
Juan Liu
-
Hui Gao
-
Tao Geng
-
July 15, 2026